A UK study found that using a polygenic risk score to identify men at highest genetic risk of prostate cancer significantly ...

A team of University of Kentucky Markey Cancer Center researchers have found the mechanism that grants prostate cancer resistance to enzalutamide, a frequently used drug treatment.

A team of University of Kentucky Markey Cancer Center researchers has found the mechanism that grants prostate cancer ...

The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

Assessing prostate-specific antigen levels for 3 months after radical prostatectomy may help minimize overtreatment, ...

Sexual function data support enzalutamide as monotherapy and combined with leuprolide in patients with high-risk biochemically recurrent prostate cancer. Enzalutamide monotherapy maintains sexual ...

Discover a study where findings revealed that total radiographic disappearance of metastases occurred in 15% of patients.

Following recent U.S. Food and Drug Administration (FDA) approval 2, and in preparation for commercial launch in H1 2025, Telix has contracted with Cardinal Health to enable availability across a wide ...

Rashes are a common side effect of some prostate cancer treatments. Rarely, they may be caused by cancer cells.

Elevated circulating tumor DNA (ctDNA) fraction and tumor suppressor gene loss are associated with worse prognosis in patients with prostate cancer liver metastases (PCLM), accord ...

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease who are eligible to receive the drug.